Partner Judy Waltz was quoted in a Bloomberg BNA article, “Health-Care Compliance Plans to Face Increased Scrutiny,” covering the Health and Human Services Officer of Inspector General’s (HHS OIG) impact on a new government focus on health-care compliance programs.
As explained in the article, Waltz explained that “the OIG has been looking at compliance program effectiveness when considering whether to negotiate corporate integrity agreements. She predicted the OIG will either expect or require organizations to put the new compliance metrics in place.”
As explained in the article, Waltz explained that “the OIG has been looking at compliance program effectiveness when considering whether to negotiate corporate integrity agreements. She predicted the OIG will either expect or require organizations to put the new compliance metrics in place.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”